Home › NCT07315165
Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation
A Phase II Randomized Trial of Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation
Who can join
Ages 19 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Diagnosis of a hematological condition or serious blood disorder * Patient planned for an allogeneic hematopoietic stem cell transplant * Any conditioning regimen or graft source Exclusion Criteria: * Uncorrected anatomical deformity of the nose, nasopharynx, esophagus, or stomach that could prevent proper placement of a nasogastric tube. * Chronic gastrointestinal conditions causing malabsorption or need for nutritional supplementation, e.g., celiac disease, short gut syndrome, chronic use of total parental nutrition or enteral nutrition for 3 or more months. Uncorrected anatomical deformity may include any known significant deviated nasal septum, large nasal polyps or other masses, or nasal or oropharyngeal trauma.
About the study
This is a randomized controlled phase II trial which will enroll 112 patients with a diagnosis of a blood cancer or a serious blood disorder who plan to undergo an allogenic hematopoietic stem cell transplant using any conditioning regimen or graft source. Eligible patients will be randomized to receive standard of care (e.g., initiation of supplemental nutrition when oral intake declines) versus enteral nutrition via enteral feeding tube starting on day +1 post-transplant for at least 7 days, usually until engraftment.
What is being tested
- Enteral Nutrition (dietary supplement)
Sponsor: University of Nebraska · Participants: 112 · Started: Jul 22, 2026
Contact the study team
- Krishna vamsi Gottipati, MS · Phone: (402) 5593518
- IIT Office Clinical Trails Office · Phone: (402) 5590963
Official record on ClinicalTrials.gov — NCT07315165
Locations in the U.S.
| Nebraska | Fred & Pamela Buffet Cancer Center, Omaha |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.